Copyright
©2010 Baishideng Publishing Group Co.
World J Hepatol. Oct 27, 2010; 2(10): 367-373
Published online Oct 27, 2010. doi: 10.4254/wjh.v2.i10.367
Published online Oct 27, 2010. doi: 10.4254/wjh.v2.i10.367
Tumor type (syndrome) | Incidence of PETs (%) | Clinical presentation | Malignancy (%) |
Insulinoma | 70-80 | Weakness, sweating, tachycardia, anxiety, fatigue, headache, dizziness, disorientation, seizures and unconsciousness | < 10 |
Gastrinoma | 20-25 | Intractable or recurrent peptic ulcer disease (hemorrhage, perforation), complications of peptic ulcer, diarrhea | 50-60 |
Non-functional tumors | 30-50 | Obstructive jaundice, pancreatitis, epigastric pain, duodenal obstruction, weight loss, fatigue | 60-90 |
VIPoma | 4 | Profuse watery diarrhea, hypotension, abdominal pain | 80 |
Glucagonoma | 4 | Migratory, necrolytic skin rash, glossitis, stomatitis, angular cheilitis, diabetes, severe weight loss, diarrhea | 80 |
Somatostatinoma | < 5 | Weight loss, cholelithiasis, diarrhea, neurofibromatosis | 50 |
Carcinoid | < 1 | Flushing, sweating, diarrhea, edema, wheezing | 90 |
ACTHoma | < 1 | Cushing’s syndrome | > 90 |
GRFoma | < 1 | Acromegaly | 30 |
PTH-like-oma | < 1 | Hypercalcemia, bone pain | > 90 |
Neurotensinoma | < 1 | Hypotension, tachycardia, malabsorption | > 80 |
- Citation: Fendrich V, Michl P, Habbe N, Bartsch DK. Liver-specific therapies for metastases of neuroendocrine pancreatic tumors. World J Hepatol 2010; 2(10): 367-373
- URL: https://www.wjgnet.com/1948-5182/full/v2/i10/367.htm
- DOI: https://dx.doi.org/10.4254/wjh.v2.i10.367